| abstract |
Disclosed are aminoisoxazole derivatives of formula (I); wherein, R is an optionally substituted 5 or 6 membered heteroaryl group with from 1 to 3 heteroatoms selected among nitrogen, oxygen and sulfur, optionally further condensed with a 5 to 7 membered aromatic or non-aromatic carbocycle or heterocycle with from 1 to 3 heteroatoms selected among nitrogen, oxygen and sulfur; X is a divalent group selected from -N(R3)- and -O-; Y is a divalent group selected from -CH(R3), -CO-, -CONH- and -SO2-, or Y may also be a single bond when R is a hydrogen atom or a C cycloalkyl group; Further disclosed are: the use of compounds of formula (I) in the manufacture of a medicament for the treatment of diseases caused by and/or associated with an altered protein kinase activity in a mammal in need thereof; for example the disease is a cell proliferative disorder selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; and processes for their production. |